1. JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders
- Author
-
Geza Ambrus-Aikelin, Katsuyuki Takeda, Anthony Joetham, Milos Lazic, Davide Povero, Angelina M. Santini, Rama Pranadinata, Casey D. Johnson, Matthew D. McGeough, Federico C. Beasley, Ryan Stansfield, Christopher McBride, Lynnie Trzoss, Hal M. Hoffman, Ariel E. Feldstein, Jeffrey A. Stafford, James M. Veal, Gretchen Bain, and Erwin W. Gelfand
- Subjects
Medicine ,Science - Abstract
Abstract The NLRP3 inflammasome is an intracellular, multiprotein complex that promotes the auto-catalytic activation of caspase-1 and the subsequent maturation and secretion of the pro-inflammatory cytokines, IL-1β and IL-18. Persistent activation of the NLRP3 inflammasome has been implicated in the pathophysiology of a number of inflammatory and autoimmune diseases, including neuroinflammation, cardiovascular disease, non-alcoholic steatohepatitis, lupus nephritis and severe asthma. Here we describe the preclinical profile of JT002, a novel small molecule inhibitor of the NLRP3 inflammasome. JT002 potently reduced NLRP3-dependent proinflammatory cytokine production across a number of cellular assays and prevented pyroptosis, an inflammatory form of cell death triggered by active caspase-1. JT002 demonstrated in vivo target engagement at therapeutically relevant concentrations when orally dosed in mice and prevented body weight loss and improved inflammatory and fibrotic endpoints in a model of Muckle–Wells syndrome (MWS). In two distinct models of neutrophilic airway inflammation, JT002 treatment significantly reduced airway hyperresponsiveness and airway neutrophilia. These results provide a rationale for the therapeutic targeting of the NLRP3 inflammasome in severe asthma and point to the use of JT002 in a variety of inflammatory disorders.
- Published
- 2023
- Full Text
- View/download PDF